CMP Therapeutics Readies EU Launch With An Eye On The U.S.
This article was originally published in The Tan Sheet
Executive Summary
CMP Therapeutics talks with large and small pharmas about distributing its micronized nasal spray, branded as Atlantic Secret. EU regulatory approval came seven years after the firm’s launch, but CEO Neil Moray Mackenzie expects much less time before a U.S. launch.
You may also be interested in...
Zicam Maker Matrixx' Sales Plummet While Legal Costs Climb
Zicam manufacturer Matrixx Initiatives' sales dropped more than 50 percent in its most recent quarter as its legal costs continue to grow
Jurors' Answers In FTC Complaint Against Prevagen Might Form A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.